For
cancer patients, the end of treatment is merely the first step on the journey
against cancer. The subsequent lengthy follow-up examinations constitute an
unrelenting "battle against recurrence". During these follow-up examinations,
numerous patients may raise the question: Why do doctors recommend the
relatively costly PET-CT scan, rather than the more familiar conventional CT or
ultrasound?
This
brings us to the "hardcore weapon" in the field of medical imaging,
PET-CT, which possesses significant diagnostic advantages in tumor recurrence
monitoring and precise disease assessment. These advantages are primarily
manifested in three core characteristics, as introduced by Professor Yu Lijuan,
Director of the Nuclear Medicine Department at Hainan Cancer Hospital:
Advantage
1: Early Warning - Capture "Active" Signals Before
"Formation"
Conventional review methods, such as CT, MRI, and ultrasound, can clearly reveal whether there are observable tumors or nodules growing inside the body, and can accurately determine their size, shape, and other visual characteristics.
However, there is a certain time lag in such examinations: from the recurrence and continuous proliferation of tumor cells to the eventual formation of a clearly identifiable mass on imaging (usually with a diameter of about 1 cm), it often takes several months or even longer. By the time it is detected, the tumor may have progressed to a new stage.
PET-CT is a veritable "metabolic scout". Its working principle is to track a tracer (such as a glucose analog) that is actively ingested by hypermetabolic cells. Recurrent tumor cells grow abnormally active, with a metabolic rate much higher than that of normal cells, and will ingest a large amount of such tracers.
Therefore, PET-CT can detect the abnormally elevated metabolic signals of tumor cell clusters when they are still extremely small and have not formed visible tumors, providing early warning of recurrence and advancing the time window for detecting tumor recurrence, thus gaining valuable time for early clinical intervention.
Advantage 2: Broader View: One scan completes "full-body patrol"
Tumor recurrence does not always occur at the original lesion site. Cunning cancer cells may metastasize to distant sites through the blood or lymphatic system, lurking quietly in any corner of the body, such as bones, distant lymph nodes, or soft tissues.
Conventional follow-up examinations often adopt a targeted approach focusing on specific areas, such as the chest after lung cancer surgery and the abdomen after intestinal cancer surgery. This examination mode may overlook metastatic lesions that occur in unexpected locations.
PET-CT can provide a "whole-body panoramic view" for tumor monitoring. By scanning, it can obtain whole-body tomographic images, which is equivalent to conducting a comprehensive and systematic examination of the entire body without any blind spots, enabling a comprehensive review and precise assessment of the condition.
This advantage is crucial for determining whether tumor recurrence is a local lesion issue or has already developed into systemic metastasis, and it also provides decisive clinical evidence for doctors to formulate subsequent treatment strategies.
Advantage 3: More Accurate Diagnosis: Distinguishing between scars and tumors, and evaluating treatment response
After tumor treatment, fibrous scar tissue may form in the surgical area or within the radiation therapy exposure range, and tissue necrosis and inflammation may also occur. These postoperative changes may also manifest as shadow-like or space-occupying signs similar to tumors in conventional imaging, which are very similar to the morphological characteristics of tumor recurrence. This has become a "grey area" in clinical imaging diagnosis.
With its unique advantage in functional metabolic imaging, PET-CT can penetrate this diagnostic fog: active tumor tissues have abnormally vigorous metabolism, which will be clearly displayed as high-metabolic "bright spots" on the image; while scar tissues and necrotic tissues without blood supply and activity will appear as low-metabolic "dark areas" due to the lack of metabolic activity.
In addition, if subsequent interventions such as chemotherapy and targeted therapy are carried out for recurrent lesions, PET-CT can also achieve early and precise evaluation of treatment efficacy. After 1-2 cycles of treatment, by comparing the changes in metabolic activity of the lesion before and after treatment, it is possible to determine whether the treatment is effective (a decrease in metabolic activity is an indication of effectiveness). This is more sensitive and faster than waiting for changes in tumor size to appear in conventional imaging (which usually takes several months), allowing doctors to grasp the treatment effect in a timely manner and adjust the treatment plan accordingly.
Hint: PET-CT is a "strategic weapon" rather than a "regular sentinel"
Professor Yu Lijuan stated that despite the obvious advantages of PET-CT in tumor recurrence monitoring, it is not a routine choice for every follow-up examination. Its clinical application always follows the principle of precise adaptation, so as to maximize its diagnostic value at critical nodes:
1. Close monitoring of high-risk patients: For patients with high-risk of recurrence, such as those with high malignancy of the primary tumor, late clinical stage, or persistent abnormal elevation of tumor markers after treatment, doctors will recommend regular (e.g., every 6-12 months) PET-CT scans to achieve comprehensive and close monitoring of the condition and capture potential recurrence signals as early as possible;
2. Differential diagnosis when suspicious signs appear: When conventional imaging examinations reveal new nodules of unknown nature, or when patients experience persistent pain, rapid weight loss of unknown causes, and unexplained elevation of tumor markers, PET-CT becomes a crucial tool for differential diagnosis, capable of accurately distinguishing the nature of the lesion and clarifying the disease progression;
3. Balance between economy and benefit: Considering the relatively high cost of PET-CT examination, for patients with low recurrence risk and long-term stable disease, adopting a follow-up plan combining conventional imaging examination with tumor marker detection is the optimal choice that balances scientificity and economy.
In summary, the core of PET-CT lies in its comprehensive diagnostic capabilities, integrating early warning, whole-body scanning, and precise differentiation. It is not a "routine sentinel" that replaces conventional follow-up examinations, but rather a "strategic scout" dispatched at critical junctures in the fight against cancer.
Regarding whether and when to undergo a PET-CT scan, please follow the professional advice of the attending physician. The doctor will develop a scientific and most personalized follow-up monitoring plan based on the patient's specific condition, tumor recurrence risk, treatment status, and economic status.
Popular science expert
Yu Lijuan
Director of Nuclear Medicine Department, Medical Imaging Department
Chief Physician
Professor, Doctoral Supervisor
Hainan cultivates top talents
Outstanding Science and Technology Worker of Hainan Province
Medical expertise
Proficient in multimodal imaging diagnosis of tumors, including X-ray, CT, MR, SPECT/CT, and PET/CT; particularly skilled in the differential diagnosis of small pulmonary nodule-like lung cancer and PET/CT diagnosis of malignant tumors in various systems throughout the body.
Clinic Hours
Multidisciplinary outpatient clinic for chest tumors
Friday morning
Pulmonary nodule clinic
Monday morning, Tuesday morning, Wednesday morning
Nuclear medicine outpatient clinic
Monday to Friday